Cis-interaction between CD52 and T cell receptor complex interferes with CD4<sup>+</sup> T cell activation in acute decompensation of cirrhosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39276679.
- Also identified by DOI 10.1016/j.ebiom.2024.105336 and PMC identifier 11418137.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Immune dysfunction contributes to a high rate of infection in patients with acute decompensation of cirrhosis. CD52 is a glycoprotein prominently expressed in lymphocytes. Immune regulation by CD52 may be involved in adaptive immune dysfunction in cirrhosis. This study aimed to investigate the function of CD52 on CD4<sup>+</sup> T cells on the blood of patients with acute decompensation of cirrhosis. The expression of CD52 in the peripheral blood lymphocytes of 49 patients with cirrhosis was investigated using flow cytometry and transcriptomics. Potential cis-membrane ligands of CD52 were discovered via proximity labelling followed by proteomics. The function of CD52 on antigen-specific activation of CD4<sup>+</sup> T cells was examined using flow cytometry in CD52 CRISPR-Cas9 knockout primary T cells. CD52 expression was elevated in CD4<sup>+</sup> T cells in acute decompensation of cirrhosis, and this elevation was correlated with increased disease severity and mortality. Components of the T cell receptor complex including TCRβ, CD3γ and CD3ε were identified and validated as cis-membrane ligands of CD52. Knockout of CD52 promoted antigen-specific activation, proliferation, and pro-inflammatory cytokine secretion. Membrane bound CD52 demonstrated cis-interaction with the T cell receptor and served as a dynamic regulator of antigen-specific activation of CD4<sup>+</sup> T cells. The upregulation of CD52 in the periphery of acute decompensation of cirrhosis hinders the recognition of the T cell receptor by MHC, contributing to impaired T cell function. The development of an alternative anti-CD52 antibody is required to restore T cell function and prevent infections in cirrhosis. This study was supported by the NIHR Imperial Biomedical Research Centre, Institute for Translational Medicine and Therapeutics (P74713), Wellcome Trust (218304/Z/19/Z), and Medical Research Council (MR/X009904/1 and MR/R014019/1).
Medical subject headings
- CD4-Positive T-Lymphocytes
- CD52 Antigen
- Lymphocyte Activation
- Liver Cirrhosis
- Receptors, Antigen, T-Cell